Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Dec
03
Today In Oncology
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Image-Only AI Model Outperforms Breast Density for 5-Year Breast Cancer Risk Stratification
Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo